CytoMed Therapeutics Issues Press Release
Ticker: GDTC · Form: 6-K · Filed: Mar 18, 2024 · CIK: 1873093
| Field | Detail |
|---|---|
| Company | Cytomed Therapeutics LTD (GDTC) |
| Form Type | 6-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, filing-update
TL;DR
CytoMed dropped a press release on 3/18, details TBD.
AI Summary
On March 18, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of this press release.
Why It Matters
This filing indicates a recent communication from CytoMed Therapeutics, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release issuance and does not contain specific financial or operational disclosures that would indicate immediate risk.
Key Players & Entities
- CytoMed Therapeutics Limited (company) — Registrant
- March 18, 2024 (date) — Date of press release issuance
FAQ
What was the subject of the press release issued by CytoMed Therapeutics on March 18, 2024?
The filing states that CytoMed Therapeutics issued a press release on March 18, 2024, but does not specify its content.
What is the Commission File Number for this Form 6-K filing?
The Commission File Number is 001-41677.
What is the principal executive office address for CytoMed Therapeutics?
The principal executive office is located at 1 Commonwealth Lane #08-22, Singapore 149544.
Is CytoMed Therapeutics filing its annual report under Form 20-F or Form 40-F?
CytoMed Therapeutics is filing its annual report under cover of Form 20-F.
When was CytoMed Therapeutics Limited formerly known as CytoMed Therapeutics Pte. Ltd.?
The date of the name change was July 16, 2021.
Filing Stats: 368 words · 1 min read · ~1 pages · Grade level 15.9 · Accepted 2024-03-18 06:01:27
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex99-1.htm (EX-99.1) — 52KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-010173.txt ( ) — 81KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: March 18, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Chairman and Director